Thursday, 26 Apr 2018

You are here

Nailfold Capillaroscopy Portends Prognosis in Systemic Sclerosis

Two reports underscore the importance of nailfold capillaroscopy (NFC) in scleroderma and have shown that nailfold capillary drop out was significantly associated with mortality in systemic sclerosis.

A study of 99 patients from the  South Australian Scleroderma Register (SASR) followed patients from 1991 to 2015. The cohort included 99 patients with limited cutaneous SSc, 30 patients with diffuse cutaneous SSc and 23 with an overlap scleroderma syndrome. Overall there were 56 deaths. 

Diffuse scleroderma had significantly greater capillary drop out compared with limited and overlap scleroderma (p<0.001). Both capillary drop out scores and antibody status were associated with mortality.

Another study from Brazil extensively studied 170 SSc patients with high-resolution computed tomography, pulmonary function tests, and Doppler echocardiography and NFC with an avascular score.  After a  mean of 10 years, 73 patients died. (Citation source https://buff.ly/2nIvHQW)

NFC avascular score was significantly associated with mortality (HR 1.64, p = 0.001). The NFC association with mortality was was stronger than that of race, gender, anticentromere antibodies, anti-topoisomerase I antibodies, form of disease, but had similar strength to the overall skin score in univariate analyses.

Capillary loss was associated with higher risk of death and be a useful tool in prognostic evaluation of SSc.   

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Fixed and Tailored Rituximab Regimens Equal in ANCA Associated Vasculitis

The French Vasculitis Study Group has published the results of the MAINRITSAN2 trial designed to  compare individually tailored versus fixed-schedule rituximab (RTX) reinfusion for remission maintenance in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs). 

Lupus Subgroup Responds to Anti-CD22

The monoclonal antibody epratuzumab showed promise as a B-cell depleting agent in patients with concomitant systemic lupus erythematosus (SLE) and Sjogren's syndrome, a post-hoc analysis of two phase III trials found.

Wear Your Pajamas to Work for Lupus

I suspect that everyone in rheumatology has a special place in their hearts for lupus patients. Their disease is so cruel, and we have so little to offer them, but the young women (and some men) that I treat keep battling on. The longer I have cared for them, the more I wanted to do for them. Managing their illness alone did not seem like enough. 

SynBioSe: Combo Rituximab and Belimumab Succeeds in Severe Refractory Lupus

One of the driving pathogenic mechanisms in systemic lupus erythematosus (SLE) is the generation of immune complexes capable of inducing netosis (NET formation) and NET-derived DNA that may be an amplifying autoantigen and give rise to anti-nuclear autoantibodies (ANAs). 

Increased Comorbidity Burden in Lupus African Americans

Researchers from Vanderbilt University Medical Center used electronic health records (EHR) to perform a phenome-wide study comparing African American (AA-SLE) and Caucasian (C-SLE) with systemic lupus erythematosus (SLE) and found more comorbidities in AA-SLE, especially renal, cardiovascular, and infectious diseases.